Chroma secures new investment of 135M for Series B in genetic medicines
Biospace - 01-Mar-2023Epigenetic medicine approach avoids the pitfalls of traditional CRISPR method of gene editing
Join the club for FREE to access the whole archive and other member benefits.
Chief Executive Officer at Chroma Medicine
Catherine is Chief Executive Officer at Chroma Medicine and an Advisor at Atlas Venture. She also serves as an Independent Board member at Generation Bio, Tenaya Therapeutics and Dyne Therapeutics, Inc. Previously, she was Chief Research and Development Officer at Obsidian Therapeutics where she led discovery efforts for their engineered cell and gene therapies. Prior to Obsidian Therapeutics, Catherine was an Entrepreneur in Residence at Atlas Venture and Chief Medical Officer at Sarepta Therapeutics.
In addition, Catherine held various leadership roles at Regeneron and Amgen. Catherine received her M.D. from the University of Chicago and trained as a nephrologist and earned her M.S. in epidemiology at University of Washington.
Highly experienced biopharmaceutical executive and physician-scientist with 15+ years of industry experience. Significant success in building and leading high-performing teams at both large and small companies.
Visit website: https://chromamedicine.com/people/catherine-stehman-breen/
See also: Chroma Medicine - Epigenetic editing company, therapy based on epigenetics
Details last updated 05-Mar-2023
Epigenetic medicine approach avoids the pitfalls of traditional CRISPR method of gene editing